Growth Differentiation Factor 15, Its 12-Month Relative Change, and Risk of Cardiovascular Events and Total Mortality in Patients with Stable Coronary Heart Disease: 10-Year Follow-up of the KAROLA Study

Dallmeier, Dhayana; Brenner, Hermann; Mons, Ute; Rottbauer, Wolfgang; Köenig, Wolfgang; Rothenbacher, Dietrich

doi:10.1373/clinchem.2016.254755

Cited by 32 publications

(27 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The eligible trials involved a total of 53 706 participants. Six studies enrolled community‐based populations, 17 studies were restricted to patients with coronary artery disease (CAD), five studies were on HF, and the remaining three were respectively pertaining to diabetes mellitus (DM), atrial fibrillation (AF) and intensive care unit patients . The mean age of the subjects ranged from 42 to 79 years.…”

Section: Resultsmentioning

confidence: 99%

“…Table showed the estimates of association between GDF‐15 levels and risk of adverse outcomes included in the meta‐analysis. Nineteenstudies individually regarded the GDF‐15 level as a continuous variable to evaluate the risk of CVDs, 7 studies only regarded the GDF‐15 level as a categorical variable and 5 studies utilized both two ways. Among the 31 trials, seven reported CVD mortality as outcomes, 13 reported complex adverse outcome, and 20 reported all‐cause mortality as outcomes.…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Growth differentiation factor‐15 and the risk of cardiovascular diseases and all‐cause mortality: A meta‐analysis of prospective studies

Xie

Liu

2019

Clinical Cardiology

View full text Add to dashboard Cite

Background and Aim Previous studies have documented that the association between growth differentiation factor‐15 (GDF‐15) the risk of patients with cardiovascular diseases (CVDs). In this meta‐analysis, our main objective is to explore the associations between GDF‐15 and the risk of CVD or all‐cause mortality. Methods PubMed and ISI Web of Science (up to January 2018) electronic databases were browsed for eligible studies. The studies provided relevant data depicted as hazard ratio (HR) with 95% confidence interval (CI), with regard to the association between GDF‐15 levels and subsequent risk of CVDs or all‐cause mortality. A random‐effect model was applied to pool the HR and 95% CI. Results Thirty‐one prospective studies met the eligibility criteria involving 53 706 subjects with 7020 adverse outcome events. It was concluded that GDF‐15 levels were associated with an incremental risk of CVDs or all‐cause mortality. Highest GDF‐15 category was associated with greater risk of cardiovascular mortality (HR, 2.66; 95% CI, 1.69‐3.63), all‐cause mortality (HR, 2.52; 95% CI, 2.06‐2.97), and complex adverse outcome (HR, 1.81; 95% CI, 1.42‐2.21). As each log‐unit increment in GDF‐15 concentration, the corresponding risk of adverse events also escalated, cardiovascular mortality (HR, 2.11; 95% CI, 1.57‐2.66), all‐cause mortality (HR, 2.70; 95% CI, 2.29‐3.12), and complex adverse outcome (HR, 1.96; 95% CI, 1.64‐2.29). Conclusions Judging from the results of the data analysis, GDF‐15 levels may increase the risk of CVDs or all‐cause mortality.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Growth differentiation factor‐15 and the risk of cardiovascular diseases and all‐cause mortality: A meta‐analysis of prospective studies

Xie

Liu

2019

Clinical Cardiology

View full text Add to dashboard Cite

show abstract

“…In communitydwelling individuals, higher concentrations of GDF-15 are associated with increased prevalence and incidence of CVD, chronic kidney disease, and cancer, independent of traditional risk factors, renal function, and other biomarkers (2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12). GDF-15 has emerged as an independent marker of all-cause mortality, cardiovascular, and noncardiovascular mortality, and nonfatal cardiovascular events in patients with coronary artery disease (13)(14)(15)(16)(17)(18)(19)(20), heart failure (21)(22)(23)(24), and atrial fibrillation (25). GDF-15 is independently associated with major bleeding in patients receiving antithrombotic therapies (20,25) and has been included in a new bleeding risk score, which may become useful for decision support (26).…”

mentioning

confidence: 99%

An Automated Assay for Growth Differentiation Factor 15

Wollert

Kempf

Giannitsis

et al. 2017

The Journal of Applied Laboratory Medicine

View full text Add to dashboard Cite

Background: Growth differentiation factor 15 (GDF-15) can serve as a biomarker for cardiovascular disease burden and risk. We evaluated a new, fully automated electrochemiluminescence immunoassay for measuring GDF-15. Methods: Six laboratories independently characterized the Elecsys ® GDF-15 assay (Roche Diagnostics) under routine conditions. Within-run precision (repeatability), within-laboratory precision (intermediate precision), and betweenlaboratory precision (reproducibility) were assessed. Plasma-serum sample correlation, reagent lot-to-lot reproducibility, and instrument comparisons were performed. The Elecsys assay was compared to a research immunoradiometric assay (IRMA) and a commercially available ELISA. GDF-15 concentrations were measured with the Elecsys assay in 739 apparently healthy individuals. Results: CVs for within-run and within-laboratory precision ranged from 0.7% to 7.7% and 1.7% to 8.6%, respectively, for samples containing 670-16 039 ng/L. CVs for between-laboratory precision ranged from 7.1% to 8.9% (766-14 289 ng/L). Recovery of GDF-15 was comparable for serum, Li-heparin plasma, K 2-and K 3-EDTA plasma, and citrated plasma, between 2 reagent lots, and on the cobas e 411 and cobas e 601 analyzers (Roche Diagnostics). GDF-15 concentrations in the clinically relevant range (400-3000 ng/L) measured with the Elecsys assay showed a good correlation and agreement with those measured by IRMA or ELISA. GDF-15 concentrations in apparently healthy individuals increased with age but did not vary by sex. Conclusions: The Elecsys GDF-15 assay demonstrates a robust analytic performance under routine conditions and provides an automated method for measuring GDF-15 concentrations in serum and plasma. IMPACT STATEMENT Growth differentiation factor 15 (GDF-15) is a biomarker of acute and chronic cellular stress that may inform therapeutic decision-making in patients with cardiovascular disease. In the present study, 6 laboratories evaluated a new, fully automated electrochemiluminescence immunoassay for GDF-15. The Elecsys ® GDF-15 assay performed with high within-run, within-laboratory, and between-laboratory precision. The recovery of GDF-15 was comparable with different sample matrices, reagent lots, and laboratory analyzers. GDF-15 concentrations measured with the Elecsys assay showed a good correlation and agreement with 2 previously described manual GDF-15 assays. This study demonstrates a robust analytical performance of the first automated GDF-15 assay under routine conditions.

show abstract

“…GDF15 был маркером кардиоваскулярных осложнений у больных сахарным диабетом 2-го типа в исследовании KAROLA. Повышение уровня GDF15 предсказывало 10-летнюю сердечно-сосудистую смертность и смертность от всех причин [70].…”

Section: белковые маркеры развития хронической сердечной недостаточноunclassified

Proteomic analysis in the diagnostics of chronic heart failure with normal ejection fraction

Свеклина

Шустов

Борисович³

et al. 2019

HERALD of North-Western State Medical University named after I.

View full text Add to dashboard Cite

This review is devoted to the analysis of information on protein-markers of chronic heart failure (CHF). The review contains current information about protein predictors of cardiovascular disease and concomitant CHF. The methodology of proteomic analysis is considered. The following conclusions were made: 1. The method of controlling the expression of individual genome sections proteomic analysis is a method of early, preclinical diagnosis of diseases, because it allows to identify the initial stages of the pathological genome in the phenotype. 2. The study of CHF protein markers is at the primary stage of accumulation of factual material, making this research direction promising. 3. In many ways, in addition to the prognostic effect of pathological protein-markers, the detection allows to understand the pathogenesis of the disease, its implementation at the molecular level. 4. In turn, determining exact molecular mechanisms of the pathological process development helps finding new treatment modalities. 5. Changes in the number of pathological protein-markers dynamics allows to predict the severity and outcome of the disease.

show abstract

Growth Differentiation Factor 15, Its 12-Month Relative Change, and Risk of Cardiovascular Events and Total Mortality in Patients with Stable Coronary Heart Disease: 10-Year Follow-up of the KAROLA Study

Abstract: BACKGROUND:This study considered whether baseline concentrations and 12-month changes of growth differentiation factor 15 (GDF-15) are associated with subsequent cardiovascular events (CVEs) and total mortality in patients with stable coronary heart disease.

Cited by 32 publications

References 28 publications

Growth differentiation factor‐15 and the risk of cardiovascular diseases and all‐cause mortality: A meta‐analysis of prospective studies

Growth differentiation factor‐15 and the risk of cardiovascular diseases and all‐cause mortality: A meta‐analysis of prospective studies

An Automated Assay for Growth Differentiation Factor 15

Proteomic analysis in the diagnostics of chronic heart failure with normal ejection fraction

Contact Info

Product

Resources

About